8 results
This study is a proof-of-efficacy, dose finding study of LCI699 in patients with mild-to-moderate uncomplicated essential hypertension in order to assess whether the BP effect, safety and tolerability of LCI699 as compared to those of placebo…
The primary objective is to show that eplerenone treatment reduces progression of disease in presymptomatic PLN R14del-carriers
Primary objective of the study is• To investigate efficacy and safety of different oraldoses of BAY94-8862 given once daily over 90 daysThe secondary objectives are:•To assess the effects of these doses on a compositeendpoint of death from any cause…
To assess the impact of eplerenone on cardiovascularmortality and morbidity in patients with acutemyocardial infarction (STEMI) when initiated withinthe first 24 hours of onset of symptoms (preferablyduring the first 12 hours)To investigate the…
In this research proposal, we aim to investigate for the first time in humans in vivo whether eplerenone promotes adenosine receptor stimulation by activating CD73. The results of these studies will provide a possible explanation for the positive…
Primary:- to investigate the safety and tolerability of the study drug after multiple oral dosing in healthy volunteersSecondary:- to investigate the effect of the study drug on potassium clearance upon oral potassium challenge after multiple oral…
With a standardized approach in a population with difficult to treat hypertension we want to explore how frequenty PHA is a cause of hypertension and what the test characteristics of the aldosterone-renin ratio are. Additionally we want to…
To test the hypothesis that LY3314814, administered orally at doses of 20 and 50 mg daily for 78 weeks, will slow the decline of AD ascompared with placebo in patients with mild AD dementia.